GS
GEVA

George Soros’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

George Soros’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-17,700
Closed -$1.12M – 315
2013
Q3 		$1.12M Buy
+17,700
New +$871K 0.01% 211

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

George Soros's GEVA Position: Q4 2013 in Review

George Soros sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 17,700 shares — an estimated $1.12M sold.

George Soros first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $1.12M in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • George Soros reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • George Soros sold 17,700 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $1.12M.
  • George Soros first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • George Soros's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.12M in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on Soros Fund Management's 13F filing for Q4 2013, filed 14 Feb 2014.